PDI signed a deal with an undisclosed major pharmaceutical company to employ 300 sales reps and is expected to reap $35–$40 million, the contract sales force provider said.
The contract followed the April termination of the firm’s agreement with AstraZeneca, which affected approximately 800 field reps and had a projected $60–$70 million impact.
“This particular ‘major pharmaceutical company’ was not necessarily in the market for additional representatives but when they saw the fact that we had some reps trained in a specific category, the light bulb went off and they thought, ‘hey, we could use those people,’” said Stephen Cotugno, PDI EVP of corporate development.
From the July 01, 2006 Issue of MM+M - Medical Marketing and Media
